BiosanaPharma
BiosanaPharma optimizes its continuous biomanufacturing with AVEVA CONNECT
BiosanaPharma manufactures biosimilars to make life-saving medicines more accessible, but continuous biomanufacturing involves a dizzying range of equipment. The company faced a massive number of process parameters and attributes scattered across multiple scales, sites, databases and devices, with no real-time monitoring of performance or failure modes. By adopting AVEVA CONNECT data services, BiosanaPharma brought together information from its development lab and its manufacturing site, ensuring data comparability, integrity and contextualization. Simple, secure sharing now provides a single source of truth fed with contextualized historical and real-time data. Teams benefit from effective visualization and robust offline analytics, complemented by SIMCA online MVDA models to track process parameters, quality attributes and excursions. Biomanufacturing is thus better optimized and supports the targeted affordability.
Testimonials
FAQ
How does AVEVA CONNECT facilitate end-to-end continuous biomanufacturing?
BiosanaPharma manufactures biosimilars in continuous mode, which involves an impressive range of equipment. AVEVA CONNECT data services centralizes process parameters and attributes from multiple sites, databases and devices in the cloud. The platform ensures data comparability, integrity and contextualization between the development lab and the manufacturing site. It is the digital backbone of modern biomanufacturing, where quality and traceability determine market access for life-saving medicines.
Why is the cloud an asset for the life sciences?
BiosanaPharma chose AVEVA CONNECT to benefit from a secure, scalable cloud platform suited to biomanufacturing. The cloud makes it easy to share data between R&D and production, access advanced analytics and ensure a single source of truth. In a sector subject to strict regulatory requirements (GxP), CONNECT brings the agility of the cloud while preserving the compliance, data integrity and end-to-end traceability required by health authorities.
How can data comparability between lab and plant be ensured?
A major challenge in biomanufacturing is transferring parameters from the development lab to the large-scale manufacturing site. AVEVA CONNECT contextualizes data: the same parameter is identified consistently regardless of where it comes from. This unification allows BiosanaPharma to compare performance, detect scale-up deviations and industrialize its processes reliably. It is fundamental to reducing the time-to-market of affordable biosimilar medicines.
Why couple a data platform with online MVDA models?
BiosanaPharma combines AVEVA CONNECT with SIMCA online MVDA (Multivariate Data Analysis) models to monitor process parameters, quality attributes and excursions in real time. This combination turns raw data into process intelligence: anomalies are detected before they affect batch quality. For a biomanufacturer, it is a critical lever for quality, compliance and productivity, securing parametric batch release and reducing the cost of poor quality.
What benefits does continuous biomanufacturing offer compared with traditional batch modes?
Continuous biomanufacturing, supported by AVEVA CONNECT at BiosanaPharma, reduces production costs, increases productivity and improves quality compared with batch modes. However, it requires constant real-time monitoring, which the cloud platform makes possible. This approach is strategic for making biosimilar medicines more accessible: by lowering unit costs and accelerating time to market, BiosanaPharma serves its mission of broadening access to life-saving treatments for patients.